Cargando…

Challenges of Anti-Mesothelin CAR-T-Cell Therapy

SIMPLE SUMMARY: In recent years, chimeric antigen receptor (CAR)-T-cell therapy has achieved good results in hematological malignancies. Clinical trials on anti-MSLN CAR-T cells have shown that they have a high safety profile but limited efficacy. This article reviews the clinical research status, o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhai, Xuejia, Mao, Ling, Wu, Min, Liu, Jie, Yu, Shicang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000068/ https://www.ncbi.nlm.nih.gov/pubmed/36900151 http://dx.doi.org/10.3390/cancers15051357

Ejemplares similares

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors
por: Zhang, Gui-Zhen, et al.
Publicado: (2019)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

Single-cell RNA-Seq reveals the potential risk of anti-mesothelin CAR T Cell therapy toxicity to different organs in humans
por: Wen, Lu, et al.
Publicado: (2022)

Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells
por: Jiang, Hua, et al.
Publicado: (2017)

The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice
por: Zhang, Qian, et al.
Publicado: (2021)

Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer
por: Cao, Bihui, et al.
Publicado: (2021)

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin
por: Pang, Nengzhi, et al.
Publicado: (2021)

Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells
por: Masoumi, Elham, et al.
Publicado: (2020)

Mesothelin as a biomarker for targeted therapy
por: Lv, Jiang, et al.
Publicado: (2019)

Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells
por: Tokatlian, Talar, et al.
Publicado: (2022)

Near infrared photoimmunotherapy with an anti-mesothelin antibody
por: Nagaya, Tadanobu, et al.
Publicado: (2016)

The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
por: Yu, Yi, et al.
Publicado: (2011)

Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer
por: Zhao, Ruocong, et al.
Publicado: (2021)

Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
por: Wang, Zhenguang, et al.
Publicado: (2021)

Modulating Mesothelin Shedding to Improve Therapy
por: Zhang, Yujian, et al.
Publicado: (2012)

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Favorable therapeutic response after anti-Mesothelin antibody–drug conjugate treatment requires high expression of Mesothelin in tumor cells
por: Lazzerini, Lea, et al.
Publicado: (2020)

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
por: Zhao, Zijun, et al.
Publicado: (2018)

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
por: Snell, Daniel, et al.
Publicado: (2023)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor
por: Zhang, Zhiwei, et al.
Publicado: (2019)

The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
por: Hilliard, Tyvette S.
Publicado: (2018)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

Mesothelin: An Immunotherapeutic Target beyond Solid Tumors
por: Faust, Joshua R., et al.
Publicado: (2022)

Correction: Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor
por: Zhang, Zhiwei, et al.
Publicado: (2020)

The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model
por: Mizukami, Tatsuzo, et al.
Publicado: (2018)

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
por: Xia, An-Liang, et al.
Publicado: (2017)

Construction and Preclinical Evaluation of (211)At Labeled Anti-mesothelin Antibodies as Potential Targeted Alpha Therapy Drugs
por: Wang, Xudong, et al.
Publicado: (2020)

Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody–drug conjugates from synthetic antibody libraries
por: Hsu, Hung-Ju, et al.
Publicado: (2021)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022)

Amatuximab and novel agents targeting mesothelin for solid tumors
por: Baldo, Paolo, et al.
Publicado: (2017)

CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities
por: Kankeu Fonkoua, Lionel A., et al.
Publicado: (2022)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants*
por: Fausther, Michel, et al.
Publicado: (2017)

Multiple proteases are involved in mesothelin shedding by cancer cells
por: Liu, Xiufen, et al.
Publicado: (2020)

Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies
por: Krug, Adrien, et al.
Publicado: (2021)

New development in CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2017)

CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression
por: Luksik, Andrew S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3qmblhdojq3aqns363trrf1mfn